Compare MasterCard Inc (MA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Recursion Pharmaceuticals Inc — how do they compare? MasterCard Inc trades at $542.91 (market cap $483.71B), while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.53B). The key difference: MasterCard Inc is far larger — about 316.2× Recursion Pharmaceuticals Inc's market cap, and MasterCard Inc pays a 0.64% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MA | RXRX | |
|---|---|---|
Market Cap | $483.71B | $1.53B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $6.79 |
52-Week Low | $471.55 | $2.84 |
Enterprise Value | $494.45B | $946.50M |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $545.00, up 0.26% today, with strong technical support at $540 and resistance at $547. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding expectations of $4.41. Revenue grew to $32.79B in 2025, and net income margin remains high at 45.88%. Analysts maintain a bullish consensus with a $634.27 price target, citing momentum in digital payments and AI integration.
Outlook remains positive given consistent earnings outperformance and strategic initiatives in AI and financial inclusion. Key risks include competitive disruption from stablecoins and elevated valuation multiples. Institutional ownership trends show continued accumulation, supporting the bullish sentiment. The stock presents a growth opportunity but requires monitoring of payment industry evolution and valuation sustainability.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
